Search through
Rabeprazole Sodium 20Mg + Domperidone 30Mg SR Pellets (CAS No: 117976-89-3, 57808-66-9) are increasingly utilized in the API intermediates market to address the growing demand for fixed-dose combinations targeting GERD and gastric dysmotility. This specialized pharmaceutical formulation benefits from the global sourcing shifts toward high purity fine chemicals that ensure consistent drug release profiles and regulatory compliance across international markets. Advanced custom synthesis services now facilitate the development of these sustained-release pellets for the CDMO growth sector, focusing on optimizing the synergistic effects of proton pump inhibitors and prokinetic agents. As an established bulk chemical supplier, we provide these components with a pharmaceutical purity of >= 99% to support the manufacturing of high-quality finished dosage forms. We are an established Rabeprazole Sodium 20Mg + Domperidone 30Mg SR Pellets api supplier with >= 99% purity globally for semi-finished formulators, providing comprehensive analytical (HPLC/NMR/MS) and supporting Rabeprazole Sodium 20Mg + Domperidone 30Mg SR Pellets COA/TDS/SDS region-specific regulatory support, reliable lead times, and worldwide supply chain capabilities.
Rabeprazole Sodium 20Mg + Domperidone 30Mg SR Pellets (CAS No: 117976-89-3, 57808-66-9) are increasingly utilized in the API intermediates market to address the growing demand for fixed-dose combinations targeting GERD and gastric dysmotility. This specialized pharmaceutical formulation benefits from the global sourcing shifts toward high purity fine chemicals that ensure consistent drug release profiles and regulatory compliance across international markets. Advanced custom synthesis services now facilitate the development of these sustained-release pellets for the CDMO growth sector, focusing on optimizing the synergistic effects of proton pump inhibitors and prokinetic agents. As an estab...
Chemical Properties & Specifications
P261, P264+P265, P272, P280, P302+P352, P305+P351+P338, P321, P333+P317, P337+P317, P362+P364, and P501
Skin Sens. 1 (96.4%)
Eye Irrit. 2A (100%)
A combination therapeutic agent containing a proton pump inhibitor and a dopamine antagonist used for the treatment of gastroesophageal reflux disease (GERD), peptic ulcers, and acid-related indigestion
A clinically formulated fixed-dose combination of rabeprazole sodium and domperidone sustained-release pellets designed to provide rapid acid reduction and improved gastric motility for the management of hypersecretory conditions and nausea.
Rabeprazole Sodium 20Mg + Domperidone 30Mg SR Pellets is a combination medication used to treat gastrointestinal disorders such as gastroesophageal reflux disease (GERD), acid reflux, heartburn, and peptic ulcers by reducing stomach acid and improving gut motility
This combination is primarily used in the pharmaceutical industry for the production of gastrointestinal medicines and antacid formulations
It is commonly formulated into sustained-release (SR) or delayed-release capsules and tablets, often featuring enteric-coated pellets to ensure optimal absorption and long-lasting relief
Standard documentation provided includes COA, TDS, impurity reports, and regulatory compliance documents to ensure high purity and pharmaceutical grade quality
Scimplify has capabilities for global distribution and custom synthesis through an integrated network of manufacturers and logistics partners with reliable lead time
The product is export ready with a standard MOQ starting from 100 kgs, with lead times for international customers depending on the shipping destination and specific grade.